CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
If you are an adult diagnosed with cancer within the last 10 years find out how you can participate.
Tumor DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer (DYNAMIC III)
Radiation Therapy and Cisplatin Alone or in Combination with Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Perioperative vs Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk RetroPeritoneal Sarcoma (STRASS 2)
Giving olaparib to patients with certain BRCA-mutated breast cancer for 1 year after they were treated with chemotherapy, surgery, or radiation significantly improved disease-free survival, according to the results that were presented last week at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and were simultaneously published in the New England Journal of Medicine. Results from the OlympiA (CCTG MA36) trial are important because they show that adding olaparib, a poly adenosine diphosphate-ribose polymerase (PARP) inhibitor, also benefits patients with early-stage disease, in addition to the drug’s known benefits in similar patients with metastatic disease. Patients in the study had BRCA 1/2 germline, or inherited, mutations and high-risk, early-stage cancer that was negative for human epidermal growth factor receptor 2 (HER2).
Venetoclax and Obinutuzumab vs DeLayed Therapy with VEnetoclax and Obinutuzumab in Asymptomatic High-Risk Patients with CLL/SLL
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)
Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
Dr. Joseph Pater, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS). The award recognizes an esteemed Canadian investigator whose contributions, vision, and leadership, have enhanced the Canadian cancer research landscape to significantly benefit the lives of people with cancer.
Dr. Elizabeth Eisenhauer, former CCTG IND Program Director and CCTG Interim Group Director, has been presented with the 2021 Canada Gairdner Wightman Award, for her dedication to transforming the fields of cancer clinical trials and cancer drug delivery.
Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from the MAC15 RxPONDER trial presented at the 2020 San Antonio Breast Cancer Symposium.
The results show that using fewer and higher doses of high-precision radiation therapy is a more effective approach for treating painful spinal tumors than conventional radiation therapy. More than twice as many patients treated with stereotactic body radiation therapy (SBRT) reported an enduring, complete reduction in pain, compared to those treated with conventional radiation.
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)
De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)
COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration
Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.
“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
An innovative clinical trial underway across Canada is providing new hope to a B.C. family braving pancreatic cancer – the deadliest cancer facing Canadians today.
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
The Lancet 397: 695 - 703, 2021Pal SK;Tangen C;Thompson IM;Balzer-Haas N;George DJ;Heng DYC;Shuch B;Stein M;Tretiakova M;Humphrey P;Adeniran A;Narayan V;Bjarnason GA;Vaishampayan U;Alva A;Zhang T;Cole S;Plets M;Wright J;Lara PN;
Eur J Can 149: 117 - 127, 2021Ethier JL;Anderson GM;Austin PC;Clemons M;Parulekar W;Shepherd L;Trasiewicz LS;Tu D;Amir E;
Journal of the National Comprehensive Cancer Network J Natl Compr Canc Netw : 1 - 6, 2021Seanthel DS;Noah W;Bishal G;Vanessa SA;Amanda PR;Louis E;Matthew CC;Kelvin KC;
Clinical Trials : 17407745211005045, 2021Cheung MC;Chan KK;Golden S;Hay A;Pater J;Prica A;Chen BE;Leighl N;Mittmann N;
Am J Hematol 96: 552 - 560, 2021Venner CP;LeBlanc R;Sandhu I;White D;Belch AR;Reece DE;Chen C;Dolan S;Lalancette M;Louzada M;Kew A;McCurdy A;Monteith B;Reiman T;McDonald G;Sherry M;Gul E;Chen BE;Hay AE;
Current Oncology 28: 1256 - 1261, 2021Prica A;Hay AE;Crump M;Mittmann N;Shepherd LE;Meyer RM;Imrie KI;Risebrough N;Djurfeldt M;Chen BE;Cheung MC;
J Clin Oncol 39, 2021Pal SK;Tangen C;Thompson IM;Haas NB;George DJ;Heng DYC;Shuch BM;Stein MN;Tretiakova MS;Humphrey P;Adeniran A;Narayan V;Bjarnason GA;Vaishampayan UN;Alva AS;Zhang T;Cole SW;Plets M;Wright J;Lara PLN;
